Phase 3a liraglutide 3 mg trial demonstrated significant weight loss and improved cardiovascular risk factors in adults with obesity and type 2 diabetes compared with placebo

Press/Media: Press / Media

PeriodJun 22 2014

Media coverage

1

Media coverage

  • TitlePhase 3a liraglutide 3 mg trial demonstrated significant weight loss and improved cardiovascular risk factors in adults with obesity and type 2 diabetes compared with placebo
    Media name/outletPipelineReview
    CountrySpain
    Date6/22/14
    PersonsRalph A Defronzo